A novel immunotherapy for the treatment of HPV+ tumors based on a chimeric Virus-like Drug Conjugate

A novel chimeric virus-like drug conjugate for the potential treatment of HPV+ tumors

The role of pigmentation in tumor treatment with virus-like drug conjugate belzupacap sarotalocan (AU-011) in an vitro and vivo model

A Phase 2 Trial of Belzupacap Sarotalocan (AU-011): An Investigational Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration

A Phase 1, Open-Label Trial to Determine Feasibility and Safety of Intramural Injection of Belzupacap Sarotalocan (AU-011) in Non-Muscle Invasive Bladder Cancer (NMIBC)

A Phase 2 Trial of Belzupacap Sarotalocan (AU-011), a First-in-Class Targeted Therapy for Choroidal Melanoma via Suprachoroidal Administration

A Phase 2 Trial of Belzupacap Sarotalocan (AU-011), an Investigational, Virus-Like Drug Conjugate (VDC) for the Treatment of Primary Indeterminate Lesions and Small Choroidal Melanoma (IL/CM) using Suprachoroidal Administration – (NCT04417530)

New Developments in Belzupacap Sarotalocan (AU-011), an Investigational Virus-Like Drug Conjugate (VDC) in Ocular Oncology

Clinical Evaluation of Belzupacap Sarotalocan (AU-011), a First-in-Class Targeted Therapy for Choroidal Melanoma with Intravitreal or Suprachoroidal Route of Administration

Topline Data from a Retrospective, Matched Case Study Evaluating Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy, Supports the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma